Loading
Total declarations
Companies
▲ Purchases (11 ops.)
▼ Sales (0 ops.)
Latest filing published 01 Oct 2026 for FILANA THERAPEUTICS, INC., €164k. Read the official filing
Filing timeline
BuySaleRichard Barry
Insider track record
Disclosed buys
11
Disclosed sells
0
Signal history
Closed purchases
Market purchases
11
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +64.1%Entry US$81.28 · Close at T+365 US$133.34
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Richard Barry: trading record in brief
Richard Barry, listed as board member, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Filana Therapeutics, Inc. and Sarepta Therapeutics, Inc. We count 19 filings; the first trade dates from 7 March 2022 and the latest from 30 September 2026.
No open-market sale appears; the market trades are 11 purchases worth €2.8M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 5 share grants and 3 option exercises. 2026 to date brings 3 purchases and no sales.
A typical purchase (the median) is worth €164k. On 2 out of 11 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
On 1 October 2026 came the latest disclosure, an open-market purchase for €164k in Filana Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Richard Barry
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations19 total
206,813 shares@ US$0.90Common StockSEC:0001437749-26-031654:0
Canonical exit: 28 Dec 2026 (T+90)
100,000 shares@ US$0.92Common StockSEC:0001437749-26-031654:1
Canonical exit: 29 Dec 2026 (T+90)
93,091 shares@ US$0.84100.0% of flowCommon StockSEC:0001437749-26-031597:0
Canonical exit: 27 Dec 2026 (T+90)
16,875 sharesCommon StockSEC:0001193125-26-260245:0
150,000 shares@ US$2.766.7% of flowCommon StockSEC:0001437749-25-036125:0
Canonical exit: 18 Feb 2026 (T+90)
73,385 shares@ US$2.753.3% of flowCommon StockSEC:0001437749-25-035882:0
Canonical exit: 17 Feb 2026 (T+90)
7,172 shares@ US$2.280.3% of flowCommon StockSEC:0001437749-25-029725:0
Canonical exit: 21 Dec 2025 (T+90)
5,400 shares@ US$2.130.2% of flowCommon StockSEC:0001437749-25-029586:0
Canonical exit: 17 Dec 2025 (T+90)
12,350 shares@ US$32.6327.2% of flowCommon StockSEC:0000950170-25-073954:0
9,746 shares@ US$25.1816.6% of flowCommon StockSEC:0000950170-25-071961:0
2,383 shares0Common StockSEC:0000950170-25-037514:0
176,085 shares@ US$22.0067.6% of flowCommon StockSEC:0001437749-24-013144:0
1,846 shares0Common StockSEC:0000950170-24-026615:0
10,000 shares@ US$78.8156.2% of flowCommon StockSEC:0001209191-23-054442:0
Canonical exit: 1 Feb 2024 (T+90)
1,906 shares@ US$16.800.5% of flowCommon StockSEC:0001069530-23-000043:0
Canonical exit: 19 Nov 2023 (T+90)
1,523 shares0Common StockSEC:0001209191-23-017401:0
11,565 shares@ US$26.135.3% of flowCommon StockSEC:0001069530-23-000011:0
Canonical exit: 4 Jun 2023 (T+90)
36,159 shares@ US$23.7916.1% of flowCommon StockSEC:0001069530-22-000041:0
Canonical exit: 21 Nov 2022 (T+90)
2,953 shares0Common StockSEC:0001209191-22-017348:0
19 of 19 declarations
